文献速递银屑病与炎症性皮肤病自身免疫性与大疱性皮肤病

GLP-1受体激动剂在化脓性汗腺炎中的应用:全国性队列研究

Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-10-03

丹麦全国登记队列纳入12581例HS、9824例银屑病和12581例对照,随访至2022年底。HS患者GLP-1RA启用率8.2%,高于银屑病5.7%和对照3.2%,且启用更早;启用后手术和系统用药减少,但匹配未启用者也有类似下降。

要点

  • HS患者GLP-1RA启用率8.2%,高于银屑病5.7%和对照3.2%
  • HS患者启用GLP-1RA平均时间8.88年,早于银屑病10.1年和对照10.2年
  • 启用GLP-1RA后手术和系统用药减少,但未启用匹配者也有类似下降

核心结论

  • HS患者较银屑病和对照更早、更频繁启用GLP-1RA。
  • GLP-1RA启用后HS相关治疗和手术使用减少,但匹配未启用者也有类似下降,组间差异无统计学意义。
  • 需进一步研究明确GLP-1RA是否直接改善HS疾病活动度。

研究设计与样本

  • 丹麦全国登记队列研究,纳入2000年1月1日至2022年12月31日成人HS、年龄性别匹配银屑病和背景对照。
  • 共纳入12581例HS、9824例银屑病和12581例对照。
  • 在HS诊断日(索引日)和GLP-1RA启用时评估合并症;在持续GLP-1RA治疗HS患者和匹配未使用者中比较启用前后2年医疗利用、手术和用药。

主要发现

  • 随访期间HS患者GLP-1RA启用率8.2%,银屑病5.7%,对照3.2%。
  • HS患者GLP-1RA启用平均时间8.88年,短于银屑病10.1年(p < 0.001)和对照10.2年(p < 0.001)。
  • 从索引日到治疗启用,所有组心代谢和精神合并症均增加。
  • GLP-1RA启用后观察到手术操作和系统用药使用率降低。
  • 匹配未启用者中观察到类似下降,组间差异无统计学意义。

临床怎么用

  • HS患者GLP-1RA启用更早更频繁,提示临床需关注其心代谢合并症负担。
  • GLP-1RA启用后HS相关治疗和手术减少,但需考虑时间趋势等混杂因素。
  • 不能仅凭本研究认为GLP-1RA直接改善HS疾病活动度,需进一步研究验证。

局限性

  • 观察性登记研究,无法确定GLP-1RA与HS结局的因果关系。
  • 匹配未启用者也有类似下降,组间差异无统计学意义,提示存在时间趋势或其他混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hidradenitis suppurativa (HS) is associated with obesity, metabolic dysfunction and increased healthcare utilization. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory effects and reduction in HS symptoms, but real-world patterns of GLP-1RA use in HS remain limited. OBJECTIVES: To investigate GLP-1RA use and comorbidity burden among patients with HS compared to matched psoriasis patients and background controls, including changes in healthcare utilization and treatment patterns following GLP-1RA initiation. METHODS: In this nationwide Danish register-based cohort study, adult patients with HS and age- and sex-matched patients with psoriasis and background controls were included from 1 January 2000 to 31 December 2022. Comorbidities were assessed at the date of HS diagnosis (index date) and at GLP-1RA initiation. Healthcare utilization, surgical procedures and medication use were examined during the 2 years before and after GLP-1RA initiation among patients with HS receiving continuous GLP-1RA treatment and matched HS non-users. RESULTS: A total of 12,581 patients with HS, 9824 patients with psoriasis, and 12,581 controls were included. During follow-up, 8.2% of patients with HS initiated GLP-1RA treatment, compared with 5.7% of psoriasis patients and 3.2% of controls. Mean time to GLP-1RA initiation was shorter among patients with HS (8.88 years) than psoriasis patients (10.1 years; p < 0.001) and controls (10.2 years; p < 0.001). Cardiometabolic and psychiatric comorbidities increased from index date to treatment initiation across all groups. Following GLP-1RA initiation, lower rates of surgical procedures and systemic medication use were observed. CONCLUSIONS: Patients with HS demonstrated earlier and more frequent use of GLP-1RA compared with psoriasis patients and controls, with decreased use of HS-specific treatments and surgical procedures following GLP-1RA initiation. Comparable declines were observed among matched non-initiators. Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that causes painful lumps and draining tunnels, most commonly in the armpits, groin and buttocks. HS affects around 1% of adults and is strongly linked to obesity, diabetes and cardiovascular disease. This study was conducted in Denmark using nationwide healthcare registries covering all Danish adults between 2000 and 2022. The aim of the study was to investigate how many patients with HS used glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), a group of medications commonly used to treat obesity and type 2 diabetes, and whether healthcare use and HS treatments changed after starting GLP‐1RA therapy. We identified 12,581 patients with HS and compared them with 9824 patients with psoriasis and 12,581 from the general population. The study examined GLP‐1RA use, comorbidities, hospital visits, surgeries and medications used before and after GLP‐1RA treatment. Patients with HS started GLP‐1RA treatment more often and at a younger age. Patients starting GLP‐1RA treatment also had a high burden of metabolic and cardiovascular diseases. After starting GLP‐1RA treatment, patients with HS showed reduced use of antibiotics and HS‐related surgical procedures over time. Similar reductions were also seen in matched patients with HS who did not start GLP‐1RA treatment, and the differences between the two groups were not statistically significant. Further studies are needed to determine whether GLP‐1RAs directly improve HS disease activity.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Nielsen VW, Holgersen N, Pedersen NH, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study. J Eur Acad Dermatol Venereol. 2026. PMID: 42828450. doi:10.1111/jdv.70769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。